Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9748472 | 0.88 | ALDH1A1 (0.54) | ALDH1A1HSD17B10GAAL3MBTL1HPGD | |
| SCHEMBL2210099 | 0.83 | ALDH1A1 (0.44) | ALDH1A1HSD17B10GAAL3MBTL1HPGD | |
| SCHEMBL13277864 | 0.81 | GAA (0.56) | ALDH1A1HSD17B10GAAL3MBTL1HPGD | |
| SCHEMBL8668228 | 0.79 | ALDH1A1 (0.44) | ALDH1A1HSD17B10GAAL3MBTL1HPGD | |
| SCHEMBL16907286 | 0.78 | RXFP1 (0.46) | ALDH1A1HSD17B10GAAL3MBTL1HPGD | |
| SCHEMBL6113785 | 0.77 | LMNA (0.46) | ALDH1A1HSD17B10GAAL3MBTL1HPGD | |
| SCHEMBL9749252 | 0.77 | GAA (0.51) | ALDH1A1HSD17B10GAAL3MBTL1HPGD | |
| SCHEMBL9748757 | 0.74 | GAA (0.49) | ALDH1A1HSD17B10GAAL3MBTL1HPGD | |
| SCHEMBL9749534 | 0.72 | APEX1 (0.54) | ALDH1A1HSD17B10GAAHPGDRAB9A | |
| SCHEMBL9749375 | 0.71 | ALDH1A1 (0.45) | ALDH1A1HSD17B10GAAL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389616-B1 | 3,4-Dihalobenzylpiperidine derivatives and their medical use | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7115635-B2 | Benzylpiperidine compound | MITSUBISHI PHARMA CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | MITSUBISHI PHARMA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1389616-A1 | NOVEL BENZYLPIPERIDINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158071-A1 | Chemokine inhibitors and stability in blood | CCL2, CXCR1, CCR5 | ALDH1A1 521/4885HSD17B10 2037/4885GAA 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.